EyeCare Partners
EyeCare Partners

Biogen Eyes Two Ophthalmic Biosimilars

Boston-based Biogen Inc. (NASDAQ: BIIB) has announced a “proposed transaction” with Samsung Bioepis Co., Ltd. to secure the exclusive rights to commercialize two new ophthalmology biosimilars, SB11 referencing Lucentis® and SB15 referencing Eylea®, in major markets worldwide, including the United States, Canada, Europe, Japan and Australia. In addition, Biogen will acquire exclusive commercialization rights for Samsung […]